Abstract:BackgroundStimulator of interferon genes (STING) has emerged as a crucial and promising target in tumor immunotherapy in recent years. Its agonists play a vital role in activating both innate and adaptive immune responses to combat cancer. Currently, STING agonists are primarily administered through intratumoral or intravenous injection, with only a few could be administered by orally. Therefore, orally available STING agonists are urgently needed to be developed.Approach and resultsBased on previous structure-activity relationship (SAR) studies, we made a structure modification to MSA-2 by replacing the carbonyl group with a difluoromethylene to get a new compound 202 (C202) that exhibited better plasma exposure and oral bioavailability than MSA-2. Thus, we conducted extensive pharmacological evaluations to understand its effects. C202 demonstrated the ability to activate various human STING isoforms and murine STING protein, showcasing a potent and specific activation of the STING signalling pathway at cellular level. In diverse immunocompetent mouse models representing both 'cold' and 'hot' tumors, C202, whether administered intratumorally or orally, displayed broad-spectrum anti-tumor activity. Encouragingly, it induced complete tumor regression in several tumor models of mice and stimulated immune memory effects, contributing to long-term immune response against cancer. Additionally, our investigations into the impact of C202 on the tumor microenvironment found that it enhanced the anti-tumor response of both innate and adaptive immune systems, bolstering the immune-mediated fight against tumors. Furthermore, we made an intriguing observation regarding C202's synergistic effects. It was found to enhance the anti-tumor activity of chemotherapy drug gemcitabine and the angiogenesis inhibitor AL3810, which provide potential combination therapies in future translational studies.ConclusionsOur research highlights C202 as a novel STING agonist with durable anti-tumor activity that can be administered orally, presenting a promising candidate for cancer immunotherapy. C202 specifically activates various STING isoforms and its downstream signalling, and exhibited high oral bioavailability and plasma exposure and displayed broad-spectrum anti-tumor activity either by local or oral administration. C202 activated both innate and adaptive anti-tumor immunity, and importantly it induced complete tumor regression and immune memory,C202 exerts synergistic effects with chemotherapy (gemcitabine) or angiogenesis inhibitor (AL3810) in anti-tumor. # image

18 F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor

18F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor

A Novel 18F-Labeled Agonist for PET Imaging of Stimulator of Interferon Gene Expression in Tumor-Bearing Mice

Development of 18F-Labeled Acridone Analogue for Tumor Imaging Via Stimulator of Interferon Genes Targeting

Preclinical Evaluation of 131I/18F-Labeled Covalent Small-Molecule Inhibitors for STING Status Imaging

Development of STING probes and visualization of STING in multiple tumor types

Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury

Discovery of Novel Thieno[2,3-d]imidazole Derivatives As Agonists of Human STING for Antitumor Immunotherapy Using Systemic Administration.

Structure−Activity Relationship Study of Benzothiophene Oxobutanoic Acid Analogues Leading to Novel Stimulator of Interferon Gene (STING) Agonists

STING-targeted PET Tracer for Early Assessment of Tumor Immunogenicity in Colorectal Cancer after Chemotherapy.

A novel STING agonist with systemic and durable anti-tumour activity

STING-driven interferon signaling triggers metabolic alterations in pancreas cancer cells visualized by [18F]FLT PET imaging.

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Abstract 6644: A Comprehensive in Vitro and in Vivo System to Evaluate STING Agonist Efficacy in Cancer Therapeutics

Development of Orally Bioavailable Amidobenzimidazole Analogues Targeting Stimulator of Interferon Gene (STING) Receptor

A Novel Near-Infrared Fluorescent Probe TMTP1-PEG4-ICG for in Vivo Tumor Imaging.

Al18F Labeled Sulfonamide‐conjugated Positron Emission Tomography Tracer in Vivo Tumor‐targeted Imaging

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

Bioorthogonal imaging probe for STING protein in live cell and fixed tissue

Immu-19. Preclinical Therapeutic Activity And Pet Imaging Of Sting Agonist 8803 In Glioblastoma

Discovery of a Photoactivatable Dimerized STING Agonist Based on the Benzo[b]selenophene Scaffold